866-997-4948(US-Canada Toll Free)

Type 2 Diabetes - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 1100 Pages

Type 2 Diabetes - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 25, 68, 64, 5, 250, 75 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 22 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 11
Type 2 Diabetes Overview 12
Type 2 Diabetes Therapeutics Development 13
Type 2 Diabetes Therapeutics Assessment 67
Type 2 Diabetes Companies Involved in Therapeutics Development 89
Type 2 Diabetes Drug Profiles 198
Type 2 Diabetes Dormant Projects 997
Type 2 Diabetes Discontinued Products 1025
Type 2 Diabetes Product Development Milestones 1035
Appendix 1043

List of Tables
Number of Products under Development for Type 2 Diabetes, H1 2017 69
Number of Products under Development by Companies, H1 2017 71
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 72
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 73
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 74
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 75
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 76
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 77
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 78
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 79
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 80
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 81
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 82
Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017 83
Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017 84
Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017 85
Number of Products under Development by Universities/Institutes, H1 2017 86
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 88
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 89
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 90
Products under Development by Companies, H1 2017 91
Products under Development by Companies, H1 2017 (Contd..1), H1 2017 92
Products under Development by Companies, H1 2017 (Contd..2), H1 2017 93
Products under Development by Companies, H1 2017 (Contd..3), H1 2017 94
Products under Development by Companies, H1 2017 (Contd..4), H1 2017 95
Products under Development by Companies, H1 2017 (Contd..5), H1 2017 96
Products under Development by Companies, H1 2017 (Contd..6), H1 2017 97
Products under Development by Companies, H1 2017 (Contd..7), H1 2017 98
Products under Development by Companies, H1 2017 (Contd..8), H1 2017 99
Products under Development by Companies, H1 2017 (Contd..9), H1 2017 100
Products under Development by Companies, H1 2017 (Contd..10), H1 2017 101
Products under Development by Companies, H1 2017 (Contd..11), H1 2017 102
Products under Development by Companies, H1 2017 (Contd..12), H1 2017 103
Products under Development by Companies, H1 2017 (Contd..13), H1 2017 104
Products under Development by Companies, H1 2017 (Contd..14), H1 2017 105
Products under Development by Companies, H1 2017 (Contd..15), H1 2017 106
Products under Development by Companies, H1 2017 (Contd..16), H1 2017 107
Products under Development by Companies, H1 2017 (Contd..17), H1 2017 108
Products under Development by Companies, H1 2017 (Contd..18), H1 2017 109
Products under Development by Companies, H1 2017 (Contd..19), H1 2017 110
Products under Development by Companies, H1 2017 (Contd..20), H1 2017 111
Products under Development by Companies, H1 2017 (Contd..21), H1 2017 112
Products under Development by Companies, H1 2017 (Contd..22), H1 2017 113
Products under Development by Companies, H1 2017 (Contd..23), H1 2017 114
Products under Development by Companies, H1 2017 (Contd..24), H1 2017 115
Products under Development by Companies, H1 2017 (Contd..25), H1 2017 116
Products under Development by Companies, H1 2017 (Contd..26), H1 2017 117
Products under Development by Universities/Institutes, H1 2017 118
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 119
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 120
Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 121
Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017 122
Number of Products by Stage and Target, H1 2017 124
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 125
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 126
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 127
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 128
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 129
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 130
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 131
Number of Products by Stage and Mechanism of Action, H1 2017 133
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 134
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 135
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 136
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 137
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 138
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 139
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 140
Number of Products by Stage and Route of Administration, H1 2017 142
Number of Products by Stage and Molecule Type, H1 2017 144
Type 2 Diabetes Pipeline by 4P Therapeutics LLC, H1 2017 145
Type 2 Diabetes Pipeline by Addex Therapeutics Ltd, H1 2017 145
Type 2 Diabetes Pipeline by Adocia, H1 2017 146
Type 2 Diabetes Pipeline by Advinus Therapeutics Ltd, H1 2017 146
Type 2 Diabetes Pipeline by Aegis Therapeutics LLC, H1 2017 147
Type 2 Diabetes Pipeline by AFFiRiS AG, H1 2017 147
Type 2 Diabetes Pipeline by Alize Pharma SAS, H1 2017 148
Type 2 Diabetes Pipeline by Allergan Plc, H1 2017 148
Type 2 Diabetes Pipeline by Alteogen Inc, H1 2017 149
Type 2 Diabetes Pipeline by Amarantus Bioscience Holdings Inc, H1 2017 149
Type 2 Diabetes Pipeline by Amgen Inc, H1 2017 150
Type 2 Diabetes Pipeline by Anchor Therapeutics Inc, H1 2017 150
Type 2 Diabetes Pipeline by AntriaBio Inc, H1 2017 151
Type 2 Diabetes Pipeline by Aphios Corp, H1 2017 151
Type 2 Diabetes Pipeline by Araim Pharmaceuticals Inc, H1 2017 152
Type 2 Diabetes Pipeline by Arena Pharmaceuticals Inc, H1 2017 152
Type 2 Diabetes Pipeline by Arisaph Pharmaceuticals Inc, H1 2017 153
Type 2 Diabetes Pipeline by ArisGen SA, H1 2017 153
Type 2 Diabetes Pipeline by Astellas Pharma Inc, H1 2017 154
Type 2 Diabetes Pipeline by AstraZeneca Plc, H1 2017 155
Type 2 Diabetes Pipeline by AusBio Ltd, H1 2017 155
Type 2 Diabetes Pipeline by Avadel Pharmaceuticals Plc, H1 2017 156
Type 2 Diabetes Pipeline by Bayer AG, H1 2017 156
Type 2 Diabetes Pipeline by Beta-Cell NV, H1 2017 157
Type 2 Diabetes Pipeline by Betagenon AB, H1 2017 157
Type 2 Diabetes Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017 158
Type 2 Diabetes Pipeline by Biocon Ltd, H1 2017 158
Type 2 Diabetes Pipeline by BioLingus AG, H1 2017 159
Type 2 Diabetes Pipeline by BioRestorative Therapies Inc, H1 2017 159
Type 2 Diabetes Pipeline by Biozeus, H1 2017 160
Type 2 Diabetes Pipeline by Biscayne Pharmaceuticals Inc, H1 2017 160
Type 2 Diabetes Pipeline by Boehringer Ingelheim GmbH, H1 2017 161
Type 2 Diabetes Pipeline by Boston Therapeutics Inc, H1 2017 161
Type 2 Diabetes Pipeline by Braasch Biotech LLC, H1 2017 162
Type 2 Diabetes Pipeline by Bristol-Myers Squibb Company, H1 2017 162
Type 2 Diabetes Pipeline by C4X Discovery Holdings PLC, H1 2017 163
Type 2 Diabetes Pipeline by Cadila Pharmaceuticals Ltd, H1 2017 163
Type 2 Diabetes Pipeline by Cardax Inc, H1 2017 164
Type 2 Diabetes Pipeline by Carmot Therapeutics Inc, H1 2017 164
Type 2 Diabetes Pipeline by Celon Pharma SA, H1 2017 165
Type 2 Diabetes Pipeline by Chipscreen Biosciences Ltd, H1 2017 165
Type 2 Diabetes Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017 166
Type 2 Diabetes Pipeline by CJ HealthCare Corp, H1 2017 166
Type 2 Diabetes Pipeline by CohBar Inc, H1 2017 167
Type 2 Diabetes Pipeline by Concenter BioPharma Silkim Ltd, H1 2017 167
Type 2 Diabetes Pipeline by ConjuChem LLC, H1 2017 168
Type 2 Diabetes Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017 168
Type 2 Diabetes Pipeline by ConSynance Therapeutics Inc, H1 2017 169
Type 2 Diabetes Pipeline by Corium International Inc, H1 2017 169
Type 2 Diabetes Pipeline by CSL Ltd, H1 2017 170
Type 2 Diabetes Pipeline by CureDM Inc, H1 2017 170
Type 2 Diabetes Pipeline by CymaBay Therapeutics Inc, H1 2017 171
Type 2 Diabetes Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017 171
Type 2 Diabetes Pipeline by Daiichi Sankyo Company Ltd, H1 2017 172
Type 2 Diabetes Pipeline by Dance Biopharm Inc, H1 2017 172
Type 2 Diabetes Pipeline by Delpor Inc, H1 2017 173
Type 2 Diabetes Pipeline by Diabetology (Products) Ltd, H1 2017 173
Type 2 Diabetes Pipeline by DiaMedica Therapeutics Inc, H1 2017 174
Type 2 Diabetes Pipeline by Diamyd Medical AB, H1 2017 174
Type 2 Diabetes Pipeline by Diasome Pharmaceuticals Inc, H1 2017 175
Type 2 Diabetes Pipeline by DiscoveryBiomed Inc, H1 2017 175
Type 2 Diabetes Pipeline by DNJ Pharma Inc, H1 2017 176
Type 2 Diabetes Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017 176
Type 2 Diabetes Pipeline by Elcelyx Therapeutics Inc, H1 2017 177
Type 2 Diabetes Pipeline by Eli Lilly and Company, H1 2017 177
Type 2 Diabetes Pipeline by Enteris BioPharma Inc, H1 2017 178
Type 2 Diabetes Pipeline by Enzo Biochem Inc, H1 2017 178
Type 2 Diabetes Pipeline by Epichem Pty Ltd, H1 2017 179
Type 2 Diabetes Pipeline by Esperion Therapeutics Inc, H1 2017 179
Type 2 Diabetes Pipeline by Eternygen GmbH, H1 2017 180
Type 2 Diabetes Pipeline by Evotec AG, H1 2017 180
Type 2 Diabetes Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 181
Type 2 Diabetes Pipeline by Generex Biotechnology Corp, H1 2017 181
Type 2 Diabetes Pipeline by Genexine Inc, H1 2017 182
Type 2 Diabetes Pipeline by Genfit SA, H1 2017 182
Type 2 Diabetes Pipeline by Genmedica Therapeutics SL, H1 2017 183
Type 2 Diabetes Pipeline by Genovate Biotechnology Co LTD, H1 2017 183
Type 2 Diabetes Pipeline by Geropharm LLC, H1 2017 184
Type 2 Diabetes Pipeline by Gilead Sciences Inc, H1 2017 184
Type 2 Diabetes Pipeline by GlaxoSmithKline Plc, H1 2017 185
Type 2 Diabetes Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017 185
Type 2 Diabetes Pipeline by Glucox Biotech AB, H1 2017 186
Type 2 Diabetes Pipeline by GW Pharmaceuticals Plc, H1 2017 186
Type 2 Diabetes Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017 187
Type 2 Diabetes Pipeline by HanAll Biopharma Co Ltd, H1 2017 187
Type 2 Diabetes Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 188
Type 2 Diabetes Pipeline by Heptares Therapeutics Ltd, H1 2017 188
Type 2 Diabetes Pipeline by HitGen LTD, H1 2017 189
Type 2 Diabetes Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017 189
Type 2 Diabetes Pipeline by Immuron Ltd, H1 2017 190
Type 2 Diabetes Pipeline by Innopharmax Inc, H1 2017 190
Type 2 Diabetes Pipeline by Innovative Targeting Solutions Inc, H1 2017 191
Type 2 Diabetes Pipeline by Intarcia Therapeutics Inc, H1 2017 191
Type 2 Diabetes Pipeline by Intas Pharmaceuticals Ltd, H1 2017 192
Type 2 Diabetes Pipeline by Integral Molecular Inc, H1 2017 192
Type 2 Diabetes Pipeline by Intercept Pharmaceuticals Inc, H1 2017 193
Type 2 Diabetes Pipeline by Intrexon Corp, H1 2017 193
Type 2 Diabetes Pipeline by Ionis Pharmaceuticals Inc, H1 2017 194
Type 2 Diabetes Pipeline by Ironwood Pharmaceuticals Inc, H1 2017 194
Type 2 Diabetes Pipeline by Islet Sciences Inc, H1 2017 195
Type 2 Diabetes Pipeline by Japan Tobacco Inc, H1 2017 195
Type 2 Diabetes Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017 196
Type 2 Diabetes Pipeline by Jenrin Discovery Inc, H1 2017 196
Type 2 Diabetes Pipeline by JHL Biotech Inc, H1 2017 197
Type 2 Diabetes Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017 197
Type 2 Diabetes Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 198
Type 2 Diabetes Pipeline by Johnson & Johnson, H1 2017 199
Type 2 Diabetes Pipeline by Kadimastem Ltd, H1 2017 200
Type 2 Diabetes Pipeline by Kadmon Corp LLC, H1 2017 200
Type 2 Diabetes Pipeline by Kareus Therapeutics SA, H1 2017 201
Type 2 Diabetes Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 201
Type 2 Diabetes Pipeline by Lead Discovery Center GmbH, H1 2017 202
Type 2 Diabetes Pipeline by Leading BioSciences Inc, H1 2017 202
Type 2 Diabetes Pipeline by Lexicon Pharmaceuticals Inc, H1 2017 203
Type 2 Diabetes Pipeline by LG Chem, Ltd., H1 2017 203
Type 2 Diabetes Pipeline by Ligand Pharmaceuticals Inc, H1 2017 204

List of Figures
Number of Products under Development for Type 2 Diabetes, H1 2017 69
Number of Products under Development by Companies, H1 2017 70
Number of Products under Development by Universities/Institutes, H1 2017 86
Number of Products by Top 10 Targets, H1 2017 123
Number of Products by Stage and Top 10 Targets, H1 2017 123
Number of Products by Top 10 Mechanism of Actions, H1 2017 132
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 132
Number of Products by Top 10 Routes of Administration, H1 2017 141
Number of Products by Stage and Top 10 Routes of Administration, H1 2017 141
Number of Products by Top 10 Molecule Types, H1 2017 143
Number of Products by Stage and Top 10 Molecule Types, H1 2017 143

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *